Global Pidotimod
Market Report
2025
The Global Pidotimod market size will be $2,344.84 Million by 2028. The Global Pidotimod Industry's Compound Annual Growth Rate will be 14.42% from 2023 to 2030.
The base year for the calculation is 2024. The historical will be 2021 to 2024. The year 2025 will be estimated one while the forecasted data will be from year 2025 to 2033. When we deliver the report that time we updated report data till the purchase date.
PDF Access: Password protected PDF file, Excel File Access: Quantitative data, PPT Report Access: For the presentation purpose, Cloud Access: Secure Company Account Access.
Share your contact details to receive free updated sample copy/pages of the recently published edition of Pidotimod Market Report 2025.
As per Cognitive Market Research's latest published report, the Global Pidotimod market size will be $2,344.84 Million by 2028. The Global Pidotimod Industry's Compound Annual Growth Rate will be 14.42% from 2023 to 2030.
2021 | 2025 | 2033 | CAGR | |
---|---|---|---|---|
Global Pidotimod Market Sales Revenue | 121212 | 121212 | 121212 | 14.42% |
Base Year | 2024 |
Historical Data Time Period | 2021-2024 |
Forecast Period | 2025-2033 |
Market Split by Form |
|
Market Split by Application |
|
Market Split by Age Group |
|
List of Competitors |
|
Regional Analysis |
|
Country Analysis |
|
Report scope is customizable as we have a huge database of Pidotimod industry. We can deliver an exclusive report Edition/Consultation as per your data requirements. Request for your Free Sample Pages.
Pidotimod Market is Segmented as below. Particular segment of your interest can be provided without any additional cost. Download the Sample Pages!
Pidotimod is an Immunostimulant, it works by modulating the immune system to trigger a protective response against bacteria or viruses that cause recurrent airway infections, this boosts immunity against these infections. The common side effects associated with Pidotimod is skin rash. Pidotimod medicine is boosting the immune system and activates cells in the blood to fight against germs to protect us from respiratory infections.
The market of Pidotimod is classified into various types including Piece, oral liquid, capsule, particle and Application of Pidotimod is in gynecology, urinary, respiratory tract infection.
The market for Pidotimod immunostimulant is increasing boosting the growth of market due to its benefit and efficacy provided in the treatment of respiratory infections in children with asthma or without asthma, Chronic Bronchitis, Chronic obstructive pulmonary disease.
For Instance, Acute respiratory infections are very common across all regions. There is increasing prevalence of acute respiratory infection cases in children, adult population due to pollution, smoking habits, sedentary lifestyle, lack of exercise. The global Burden of Disease Study stated lower respiratory infection led to death of around 2.73 million people.
Hence the Pidotimod medicine has proven as effective in boosting the immunity in the patients with respiratory infections, the consumption or treatment of Pidotimod Immune stimulant reduces the severity and recurrent episodes of respiratory infection in children and adults. The efficacy and quality of pidotimod is proven for effectively treating the respiratory infection such as Recurrent respiratory infection, asthma, bronchitis, chronic obstructive pulmonary disease (COPD).
The clinical studies have proven that immunostimulant activity of pidotimod has established its prominence and it efficiently helps in management of recurrent respiratory infections in children with or without asthma and significantly prevents the recurrent infection and reduces the severity and duration of acute episodes, ultimately resulting in reduced visits to pediatric clinics and lower absenteeism at school. This benefits and efficacy of Pidotimod immunostimulant boost the growth of market.
Rise in sedentary lifestyle has led to the increase in various diseases, especially cardiovascular diseases. According to the Center for Disease Control (CDC), 30.3 million people in the US had cardiovascular diseases in 2018.
Increase in occurrence of cardiovascular diseases has propelled spending on medicines, thereby driving the demand for pidotimod. Pidotimod is used for the treatment of the Chronic obstructive pulmonary disease (COPD), and other immunity diseases, which drives the adoption of the pidotimod.
Around the US, around 805,000 people in the US have a heart attack, leading to the adoption of the pidotimod.
Additionally, rise in urbanization has led to the adoption of sedentary lifestyle. This has led to the increase in chronic diseases across the world.
Chronic diseases are among the major factors for the death across the world. It is estimated that 45% of people in the US have chronic diseases. This has led to the rise in spending on the treatment of diseases and fuelled the adoption of medicines, ie the pidotimod, which in turn, drives the market.
Socio-economic disparities are some of the major factors, which have increased the burden among the people.
Prevalence of chronic diseases has increased, which has led to the adoption of pidotimod and several other new medicines. This drives the growth of the market. Increasing adoption of sedentary lifestyle has contributed to the rise in chronic diseases.
We have various report editions of Pidotimod Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.
The reintroduction of tariffs under President Trump’s “Liberation Day Tariffs” in April 2025 has created significant disruption in global pharmaceutical trade. These tariffs, ranging from 10% to 46%, specifically target pharmaceutical products, APIs (active pharmaceutical ingredients), medical packaging, and machinery from key manufacturers in China and India. This has led to increased production costs, supply chain delays, and regulatory challenges for U.S.-based pharmaceutical companies.
The tariffs have particularly impacted generic drug manufacturers, who rely heavily on APIs from China and India. Biopharmaceuticals and vaccines are also feeling the pressure, with tariffs on critical materials like bioproduction media and cold-chain packaging raising costs by up to 25%. Similarly, contract manufacturing organizations (CMOs) are grappling with the need to identify new suppliers and adjust production plans to mitigate rising costs.
Foreign governments, including the European Union, have retaliated with tariffs on U.S. pharmaceutical exports, further complicating global trade. Clinical trials are also impacted, as tariffs on drugs and diagnostic kits delay trial timelines.
Market research is increasingly crucial for navigating these challenges. By providing real-time data on API pricing, supplier reliability, and tariff impact, pharmaceutical firms can make informed decisions on sourcing, compliance, and investment strategies. This data-driven approach helps mitigate risks, optimize supply chains, and identify alternative manufacturing hubs to offset tariff-related disruptions.
Overall, market research is essential for pharmaceutical companies to adapt to the new tariff landscape, enabling them to maintain competitive advantage and navigate global trade dynamics effectively.
Merck company is leader in science and technology, which boost its growth in market through innovation and advancement in the product portfolio. Company is leader in life science segment and post-acquisition it has significant presence across all regions along with investment in the life science industry in order to strengthen its presence in the market. Merck KGaA has wide range product portfolio in the market in healthcare, life science and performance materials segments, among which healthcare is biggest segment includes biopharma and allergopharma subsegments in it. The API product include Pidotimod that effectively used in treatment of acute recurrent respiratory tract infections. The company’s life science segment comprises of biopharmaceuticals and high-grade chemicals manufacturing such as chemical synthesis of thiols or mercaptans and other organic or inorganic chemicals, analytical chromatography products, life science, material science. The performance material segment includes specialty chemical business of Merck and supply solutions for displays, electronic chips and other. The Merck company has a subsidiary named Sigma Aldrich or currently operated under Sigma Millipore name is a part of Merck KGaA company. After acquisition with Sigma Aldrich, company serves life science segment handling established brands such as SAFC and Bio reliance. SAFC is a fine chemical supply branch, which is specialized in raw materials for cell culture, manufacturing of active pharmaceutical ingredients. It has skilled professionals, which are specialized in healthcare, life science and performance material segment and provide unique solutions to customers.
October 2020
Merck Company Merged with Mammoth Company
Merck Company collaborates with Mammoth company in Life sciences segment for the development and production of Mammoth’s CRISPR-based SARS Cov-2 diagnostic test.
July 2020
Merck company announced Expansion of Life Science Segment
Merck Company announces expansion of their Life Science segment production capacities in the Unites States. The announced to strengthen and expand their manufacturing foot prints with significant investment at its production facility in Danvers, Massachusetts, Jaffrey, New Hampshire, USA.
Dr. Reddy Laboratories is an integrated pharmaceutical company committed to provide affordable and innovative medicines for ensuring healthy wellbeing of customers. Dr Reddy's company is specialized in manufacturing and supply of quality API including Pidotimod, generic medicines. The company is preferred API partner to other pharma companies in supply of API, generic products across US, Europe, Latin America, Japan, China, Korea and emerging markets. The portfolio includes generic medicines containing tablets, capsules, injectables, and topical creams, is the largest part of our business portfolio, making products across the major therapeutic areas of gastrointestinal ailments, cardiovascular disease, pain management, oncology, anti-infective, pediatrics and dermatology. The other two segment includes pharmaceutical services and active pharmaceutical ingredient such as Pidotimod, proprietary product segment. Company has offered more than 200 high quality generic versions of expensive innovator medicines at low-cost.
2020
Dr. Reddy Laboratories has Collaborated with Fujifilm and Global Response Aid
Dr Reddy's Laboratories has collaborated with Fujifilm and Global Response Aid for distributing Avigan (Favipir) and acquired licensing rights for Redyx (Remdesivir) offered in 127 countries.
Top Companies Market Share in Pidotimod Industry: (In no particular order of Rank)
If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.
Region and country analysis section of Pidotimod Industry Analysis has been segmented into 5 major region such as North America, Europe, Asia Pacific, Middle East & Africa ,and Latin America (along with respective major contributing countries) and provides the revenue share, current trends.
The base years considered for all the estimations by analyzing trends and growth rate will help you gain an in-depth understanding of the conclusions provided in this report. This report also includes figures, graphs, pie charts, tables and bar graphs that explain the data analysis based on current trends at the country level as well as key regions. This research report also focuses on assessing factors such as profit, product price, capacity, production, supply demand market growth rate along with others to create a clear picture on the future prospects of Pidotimod market.
The current report Scope analyzes Pidotimod Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com
The above graph is for illustrative purposes only.
To learn more about geographical trends request the free sample pages.
Get Free Sample
Global Pidotimod Market Report 2025 Edition talks about crucial market insights with the help of segments and sub-segments analysis. In this section, we reveal an in-depth analysis of the key factors influencing Pidotimod Industry growth. Pidotimod market has been segmented with the help of its Form, Application Age Group, and others. Pidotimod market analysis helps to understand key industry segments, and their global, regional, and country-level insights. Furthermore, this analysis also provides information pertaining to segments that are going to be most lucrative in the near future and their expected growth rate and future market opportunities. The report also provides detailed insights into factors responsible for the positive or negative growth of each industry segment.
The Oral Liquid segment Revenue will be USD 692.84 Million by 2028.
Pidotimod is an immunostimulant that treats respiratory tract infection with or without asthma condition in children or adults. The Pidotimod is under brand name Immulina Oral Liquid available as an oral liquid used to prevent recurrent episodes of bacterial or viral infection in respiratory tract and improves immunity to protect individual form recurrence of attacks, shortens the duration of infection in patients. Immulina Liquid contains 400mg Pidotimod in liquid dosage form taken orally with or without food and advisable to consume at same time every day. Immulina Liquid is used to treat many diseases of the respiratory tract caused by bacteria or viruses. It stimulates your immune system’s response to these conditions and helps fight these infections. The side effects of Immulina oral liquid are skin rash. Immulina Liquid is an immunostimulant. It works by modulating the immune system to trigger a protective response against bacteria or viruses that cause recurrent airway infections. This boosts immunity against these infections. The other brand name of pidotimod is Polimod Oral Liquid.
Pidotimod capsule is a synthetic immunomodulatory that stimulates immunity, humoral immunity, cellular immunity that effectively treats respiratory infections. Pidotimod capsules manufactured by Changzhou Yinsheng Pharmaceutical Co. Ltd. used in treatment of recurrent respiratory infections. It significantly reduces severity of respiratory infections such as chronic bronchitis, Chronic obstructive pulmonary disease. It is used in upper and lower respiratory tract, urinary infections. Pidotimod is an immunostimulant improving immune system that provides protection against foreign substance in the body and prevent recurrent attack of respiratory, urinary tract infections. The Pidotimod is available in solid dosage form in capsules with different brands such as Pidolet 800mg, 400mg tablet, Polimod tablet. These are different brands that effectively treats respiratory infection recurrent attacks, shortens the duration of treatment.
The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Pidotimod Industry. Request a Free Sample PDF!
The Gynecological Infection segment Revenue (USD Million) in Pidotimod will be USD 12.81 Million by 2028.
Oral Pidotimod is used in treatment of Gynaecology tract infections and it is given alone or with Vitamin C. The pidotimod has proven efficacy in treating gynaecology infection.
Pidotimod is an immunostimulant that enhances the immune system and it has proven efficacy and safety of pidotimod in the treatment of urinary tract infections in children. Pidotimod along with antibiotics is used as an immunostimulant agent used for treating urinary tract infection in children.
Pidotimod is an immunostimulant that improves the immunity system and is efficiently used in the treatment of recurrent respiratory infections in children with or without asthma. Pidotimod is effective in the prevention and treatment of acute infectious exacerbations of chronic bronchitis and chronic obstructive pulmonary disease (COPD) and is also used in indications such as pneumonia, hand–food–mouth disease, bronchiectasis, chronic idiopathic urticaria. Enhancement of immunity with pidotimod has proven efficacy in the treatment of recurrent respiratory infections.
The above Graph is for representation purposes only. This chart does not depict actual Market share.
To learn more about market share request the free sample pages.
Get Free Sample
Senior Research Associate at Cognitive Market Research
Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.
Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over three years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies.
In her current role, Manjiri handles the market research related to Pharma and healthcare industry. Her passion lies in utilizing innovative approaches to distill complex information into strategic insights that empower organizations to make informed decisions.Manjiri remains an invaluable asset in the dynamic landscape of market research.
Our study will explain complete manufacturing process along with major raw materials required to manufacture end-product. This report helps to make effective decisions determining product position and will assist you to understand opportunities and threats around the globe.
The Global Pidotimod Market is witnessing significant growth in the near future.
In 2023, the Oral Liquid segment accounted for noticeable share of global Pidotimod Market and is projected to experience significant growth in the near future.
The Gynecological Infection segment is expected to expand at the significant CAGR retaining position throughout the forecast period.
Some of the key companies Active Peptide Company, Manus Aktteva Biopharma and others are focusing on its strategy building model to strengthen its product portfolio and expand its business in the global market.
Please note, we have not disclose, all the sources consulted/referred during a market study due to confidentiality and paid service concern. However, rest assured that upon purchasing the service or paid report version, we will release the comprehensive list of sources along with the complete report and we also provide the data support where you can intract with the team of analysts who worked on the report.
Disclaimer:
Form | Oral Liquid, Capsules/ Tablets |
Application | Gynecological Infection, Urinary Tract Infection (UTI), Respiratory Infections, Others |
Age Group | Children, Adults |
List of Competitors | Active Peptide Company, Reco Tech, Manus Aktteva Biopharma, Joyochem, Changzhou Yinsheng Pharmaceutical, Dr. Reddys, Merck KGaA (Sigma Aldrich) |
This chapter will help you gain GLOBAL Market Analysis of Pidotimod. Further deep in this chapter, you will be able to review Global Pidotimod Market Split by various segments and Geographical Split.
Chapter 1 Global Market Analysis
Global Market has been segmented on the basis 5 major regions such as North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.
You can purchase only the Executive Summary of Global Market (2019 vs 2024 vs 2031)
Global Market Dynamics, Trends, Drivers, Restraints, Opportunities, Only Pointers will be deliverable
This chapter will help you gain North America Market Analysis of Pidotimod. Further deep in this chapter, you will be able to review North America Pidotimod Market Split by various segments and Country Split.
Chapter 2 North America Market Analysis
This chapter will help you gain Europe Market Analysis of Pidotimod. Further deep in this chapter, you will be able to review Europe Pidotimod Market Split by various segments and Country Split.
Chapter 3 Europe Market Analysis
This chapter will help you gain Asia Pacific Market Analysis of Pidotimod. Further deep in this chapter, you will be able to review Asia Pacific Pidotimod Market Split by various segments and Country Split.
Chapter 4 Asia Pacific Market Analysis
This chapter will help you gain South America Market Analysis of Pidotimod. Further deep in this chapter, you will be able to review South America Pidotimod Market Split by various segments and Country Split.
Chapter 5 South America Market Analysis
This chapter will help you gain Middle East Market Analysis of Pidotimod. Further deep in this chapter, you will be able to review Middle East Pidotimod Market Split by various segments and Country Split.
Chapter 6 Middle East Market Analysis
This chapter will help you gain Middle East Market Analysis of Pidotimod. Further deep in this chapter, you will be able to review Middle East Pidotimod Market Split by various segments and Country Split.
Chapter 7 Africa Market Analysis
This chapter provides an in-depth analysis of the market share among key competitors of Pidotimod. The analysis highlights each competitor's position in the market, growth trends, and financial performance, offering insights into competitive dynamics, and emerging players.
Chapter 8 Competitor Analysis (Subject to Data Availability (Private Players))
(Subject to Data Availability (Private Players))
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
This chapter would comprehensively cover market drivers, trends, restraints, opportunities, and various in-depth analyses like industrial chain, PESTEL, Porter’s Five Forces, and ESG, among others. It would also include product life cycle, technological advancements, and patent insights.
Chapter 9 Qualitative Analysis (Subject to Data Availability)
Segmentation Form Analysis 2019 -2031, will provide market size split by Form. This Information is provided at Global Level, Regional Level and Top Countries Level The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 10 Market Split by Form Analysis 2021 - 2033
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 11 Market Split by Application Analysis 2021 - 2033
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 12 Market Split by Age Group Analysis 2021 - 2033
This chapter helps you understand the Key Takeaways and Analyst Point of View of the global Pidotimod market
Chapter 13 Research Findings
Here the analyst will summarize the content of entire report and will share his view point on the current industry scenario and how the market is expected to perform in the near future. The points shared by the analyst are based on his/her detailed in-depth understanding of the market during the course of this report study. You will be provided exclusive rights to interact with the concerned analyst for unlimited time pre purchase as well as post purchase of the report.
Chapter 14 Research Methodology and Sources
Charts/Graphs/Numbers are only for Representative purposes and do not depict actual statistics purchase report access or contact our team Request Sample.
Charts/Graphs/Numbers are only for Representative purposes and do not depict actual statistics purchase report access or contact our team Request Sample.
Charts/Graphs/Numbers are only for Representative purposes and do not depict actual statistics purchase report access or contact our team Request Sample.
Charts/Graphs/Numbers are only for Representative purposes and do not depict actual statistics purchase report access or contact our team Request Sample.
Charts/Graphs/Numbers are only for Representative purposes and do not depict actual statistics purchase report access or contact our team Request Sample.
Charts/Graphs/Numbers are only for Representative purposes and do not depict actual statistics purchase report access or contact our team Request Sample.
Charts/Graphs/Numbers are only for Representative purposes and do not depict actual statistics purchase report access or contact our team Request Sample.
Charts/Graphs/Numbers are only for Representative purposes and do not depict actual statistics purchase report access or contact our team Request Sample.
Why Oral Liquid have a significant impact on Pidotimod market? |
What are the key factors affecting the Oral Liquid and Capsules/ Tablets of Pidotimod Market? |
What is the CAGR/Growth Rate of Gynecological Infection during the forecast period? |
By type, which segment accounted for largest share of the global Pidotimod Market? |
Which region is expected to dominate the global Pidotimod Market within the forecast period? |
Segmentation Level Customization |
|
Global level Data Customization |
|
Region level Data Customization |
|
Country level Data Customization |
|
Company Level |
|
Additional Data Analysis |
|
Additional Qualitative Data |
|
Additional Quantitative Data |
|
Service Level Customization |
|
Report Format Alteration |
|